Overview

Our T-cell therapy targeting the NY-ESO peptide, which is present across multiple cancer types, is partnered with GSK. Following option exercise, the NY-ESO program is being transferred to GSK during a transition period.

Our NY-ESO SPEAR T-cell has been used in multiple Phase 1/2 clinical trials in patients with solid tumors and haematological malignancies, including synovial sarcoma, myxoid round cell liposarcoma, multiple myeloma, melanoma, NSCLC and ovarian cancer. We have seen responses and evidence of tumor reduction in patients with both synovial sarcoma and multiple myeloma.The initial data suggest a promising risk/benefit profile. Breakthrough therapy designation in the United States and PRIME regulatory access in Europe have been granted to the NY-ESO SPEART T-cell.

Read more about our strategic collaboration with GSK.

Pipeline

Program Indications Pre-Clinical Phase I/II Registration
NY-ESO 1 Synovial Sarcoma
Pre-Clinical Phase complete
Phase I/II Phase in progress
Registration Phase not started
MRCLS 2
Pre-Clinical Phase complete
Phase I/II Phase in progress
Registration Phase not started
NSCLC (lung)
Pre-Clinical Phase complete
Phase I/II Phase in progress
Registration Phase not started
NY-ESO + Keytruda Multiple Myeloma 3
Pre-Clinical Phase complete
Phase I/II Phase in progress
Registration Phase not started
  1. Adaptimmune’s accrual complete. Option exercised by GSK on 7th September 2017
  2. MRCLS = myxoid/round cell liposarcoma
  3. Ongoing

GSK exercised its option to exclusively license the right to research, develop, and commercialize NY-ESO SPEAR T-cell therapy program in September 2017. Transition of this program to GSK is ongoing.

Our Clinical Trials